Overview
- GeneDx reported first-quarter 2026 results that missed expectations and disclosed a $31.2–$31.3 million impairment tied to Fabric Genomics, then cut full-year revenue guidance and saw its stock fall about 49%.
- Multiple plaintiff-side firms have filed or announced investigations and suits seeking to represent investors who bought GeneDx stock between April 16, 2025 and May 4, 2026 and are soliciting lead plaintiffs and class members.
- The complaints say GeneDx misled investors by overstating the benefits of the April 2025 Fabric acquisition and by presenting its average reimbursement rate as durable when an adverse shift toward genome tests lowered ARR and margins.
- Litigation is in the early stage with the class not yet certified and firms publicizing filing windows and deadlines for potential lead plaintiffs as they build claims under Sections 10(b), 20(a) and Rule 10b-5.
- If the suits proceed, investors can pursue recoveries and the company may face extended discovery that could reveal when executives learned of Fabric’s problems and how product-mix changes altered revenue and margins.